Search Results
Jul 23, 2026, 01:37 ET THE LEGO GROUP INTRODUCES THE LEGO® SMART PLAY™ GATEWAY AT SAN DIEGO COMIC-CON 2026
highlighting a full range of LEGO Pokémon™ sets available this year.Destination: Mos EisleyDestination: Mos Eisley transports Star Wars™ fans straight to Mos Eisley Cantina, recreated as a series of oversized LEGO brick environments pulled directly from
More news about: The LEGO Group
Jul 17, 2026, 09:15 ET A Junior Just Flew 2,320 Line-Kilometres Over Northern BC and Found Out Its Scattered Showings Were One System All Along
numerous tungsten-bearing skarn intervals, including 13.0 metres grading 0.55% WO₃, 11.3 metres grading 0.59% WO₃ with 0.10% MoS₂, and 4.0 metres grading 1.32% WO₃ with 0.26% MoS₂.Those are meaningful numbers, and they need their qualifier stated as clearly as the Company states it: a Qualified Person
More news about: USA News Group
Jul 15, 2026, 16:15 ET MOSAIC ANNOUNCES SECOND QUARTER 2026 EARNINGS RESULTS DATES
TAMPA, Fla., July 15, 2026 /PRNewswire/ -- The Mosaic Company (NYSE: MOS) plans to release second quarter 2026 earnings results on Tuesday, August 4th, following the close of trading on the New York Stock Exchange. The company
More news about: The Mosaic Company
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
worldwide. Platinum-based chemotherapy remains the standard first-line treatment for patients with advanced EP-NEC, with a median overall survival (mOS) of approximately one year. However, there are no effective treatment options following progression on first-line platinum-based chemotherapy. For patients
More news about: Nanjing Leads Biolabs Co., Ltd.
Jun 22, 2026, 10:15 ET Semiconductor Intellectual Property (IP) Market worth $18.64 billion by 2032 - Exclusive Report by MarketsandMarkets™
E-Nose Market Size, Share & Trends by Application (Quality Control, Quality Assurance), Inspection Type (Inline, Laboratory), Sensor Type (MOS Sensors, Polymer Sensors, Optical Sensors, QCM Sensors, SQW Sensors), and End Use Industry - Global Forecast to 2032
More news about: MarketsandMarkets
Jun 19, 2026, 10:01 ET Automotive Sensors Market worth $109.85 billion by 2032 - Exclusive Report by MarketsandMarkets™
E-Nose Market Size, Share & Trends by Application (Quality Control, Quality Assurance), Inspection Type (Inline, Laboratory), Sensor Type (MOS Sensors, Polymer Sensors, Optical Sensors, QCM Sensors, SQW Sensors), and End Use Industry - Global Forecast to 2032
More news about: MarketsandMarkets
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
responses (30.19%). Median progression-free survival (mPFS) was 3.9 months and median duration of response (mDOR) was 5.98 months. Median overall survival (mOS) was 19.4 months, with a 12-month OS rate of 72.7% and a 24-month OS rate of 49.1%.Among the 31 post-IO patients evaluable
More news about: Mabwell
Jun 18, 2026, 10:15 ET Computerized Maintenance Management System Market worth $2.67 billion by 2032 - Exclusive Report by MarketsandMarkets™
E-Nose Market Size, Share & Trends by Application (Quality Control, Quality Assurance), Inspection Type (Inline, Laboratory), Sensor Type (MOS Sensors, Polymer Sensors, Optical Sensors, QCM Sensors, SQW Sensors), and End Use Industry - Global Forecast to 2032
More news about: MarketsandMarkets
Jun 17, 2026, 01:39 ET Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
The 6-month EFS rate was 67.8% versus 55.5% in the control group, and the 9-month EFS rate was 53.2% versus 14.1%.Median overall survival (mOS) was not reached in the ligufalimab group versus 8.3 months in the control group (HR = 0.46). The 6-month OS rate was 83.3% versus 73.2%, and the 9-month
More news about: Akeso, Inc.
Jun 12, 2026, 10:15 ET E nose Market worth $1.84 billion by 2032 - Exclusive Report by MarketsandMarkets™
deployments of e-nose across production environments.The metal oxide semiconductor (MOS) sensors captured the largest share of the E-nose market in 2025.By sensor type, the metal oxide semiconductors (MOS) segment captured the largest market share of the E-nose market in 2025 due to its high
More news about: MarketsandMarkets
Jun 05, 2026, 10:01 ET Smart Manufacturing Market worth $995.67 billion by 2032 - Exclusive Report by MarketsandMarkets™
is expected to account for the second-largest share during the forecast period.Based on technology, the manufacturing operations system (MOS) segment is expected to account for the second-largest share during the forecast period. The segment holds a significant position in the smart manufacturing
More news about: MarketsandMarkets
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS
More news about: Vcare PharmaTech
Jun 03, 2026, 17:44 ET Red Bull Basement ayuda a emprendedores a convertir su idea en una empresa emergente financiada
personas ciegas y con discapacidad visual; SIGNIVO de Bélgica, un guante inteligente con IA que convierte el lenguaje de señas en palabras habladas; LU-MOS de Japón, una plataforma rover de estándar común para operaciones lunares; y TruthShield AI de Canadá, un escudo de detección facial con IA activada."No
More news about: Red Bull
Jun 03, 2026, 13:45 ET Red Bull Basement hilft Gründern dabei, ihre Idee in ein finanziertes Start-up zu verwandeln
sehbehinderte Menschen taktil macht; das belgische „SIGNIVO", ein KI-Smart-Handschuh, der Gebärdensprache in gesprochene Worte umwandelt; das japanische „LU-MOS", eine auf einem gemeinsamen Standard basierende Rover-Plattform für Mondmissionen; sowie das kanadische „TruthShield AI", ein agentisches KI-Gesichtserkennungs-Schutzschild.„Es
More news about: Red Bull
Jun 03, 2026, 13:41 ET Red Bull Basement aide les fondateurs à exploiter le potentiel de la programmation intuitive pour transformer leur idée en jeune pousse financée
malvoyantes ; le projet belge SIGNIVO, un gant intelligent alimenté par l'IA qui convertit la langue des signes en langage parlé ; le projet japonais LU-MOS, une plateforme d'astromobile standard pour les missions lunaires ; et le projet canadien TruthShield AI, un bouclier de détection de fausses informations
More news about: Red Bull
Jun 03, 2026, 04:12 ET Red Bull Basement Is Helping Founders Vibe Code Their Idea Into a Funded Startup Reality
museum art tactile for blind and visually impaired people; Belgium's SIGNIVO, an AI smart glove that converts sign language into spoken words; Japan's LU-MOS, a common-standard rover platform for lunar operations; and Canada's TruthShield AI, an agentic AI face detection shield."This wasn't just about
More news about: Red Bull
Jun 03, 2026, 04:00 ET Red Bull Basement Is Helping Founders Vibe Code Their Idea Into a Funded Startup Reality
museum art tactile for blind and visually impaired people; Belgium's SIGNIVO, an AI smart glove that converts sign language into spoken words; Japan's LU-MOS, a common-standard rover platform for lunar operations; and Canada's TruthShield AI, an agentic AI face detection shield."This wasn't just about
More news about: Red Bull
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
8 PR), which drew attention upon abstract release on May 22, the presentation also disclosed progression-free survival (mPFS) and overall survival (mOS) data for the first time.According to the research poster presented by Tiumbio at ASCO 2026, as of the data cutoff date of March 31, 2026, the
More news about: TiumBio
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
months in the ivonescimab arm (the final death event in this arm caused the Kaplan-Meier curve to drop sharply to the median, thereby producing the mOS estimate) versus 23.7 months in the control arm.The 12-month OS rate was 78.9% with ivonescimab plus chemotherapy versus 72.2% in the control
More news about: Akeso, Inc.
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September
More news about: Dizal Pharmaceutical
May 28, 2026, 19:26 ET Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
patient populations in pivotal Phase 3 trials. Median progression-free survival (mPFS) was 7.3 months, and median overall survival (mOS) was 14.7 months in US patients, where the median follow up time is 14.7 months. The efficacy data for 3 mg/kg spevatamig + GnP is
More news about: Phanes Therapeutics, Inc.
May 28, 2026, 02:46 ET Hon'ble MoS Shri Suresh Gopi Reviews Progress of BPCL's Key Projects in Tamil Nadu
content:https://www.prnewswire.com/in/news-releases/honble-mos-shri-suresh-gopi-reviews-progress-of-bpcls-key-projects-in-tamil-nadu-302784082.html
More news about: Bharat Petroleum Corporation Limited (BPCL)
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
2.4 mg/kg, respectively, with corresponding DCRs of 86.7% and 90.0%. Median PFS (mPFS) was 6.97 months and 5.09 months, respectively, while median OS (mOS) was not yet reached in the 1.8 mg/kg cohort and was 14.72 months in the 2.4 mg/kg cohort. In the 1.8 mg/kg cohort, the incidence of Grade 3 or higher
More news about: Antengene Corporation Limited
May 26, 2026, 10:35 ET Tungsten's 557% Run Meets a District-Scale Critical-Minerals Story in British Columbia
drilling and sampling at the Kuhn Zone reportedly returned intervals including 13.0 metres grading 0.55% WO₃, 4.0 metres grading 1.32% WO₃ and 0.26% MoS₂, and 2.5 metres grading 0.95% WO₃.Third, elevated indium values of up to 334 ppm have been identified within sphalerite-bearing mineralization
More news about: Equity Insider
May 21, 2026, 17:00 ET Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Long-term follow-up reinforces PFS and OS benefit of lucicebtide plus standard of care in ndGBM: mPFS projected at 28.4 months, mOS not yet reached with 6 of 9 patients alive TARRYTOWN, N.Y., May 21, 2026
More news about: Sapience Therapeutics, Inc.